Bioxodes is a biopharmaceutical company developing drug candidates for thrombo-inflammatory diseases. Its lead program, BIOX-101, is a recombinant protein in clinical trials for intracerebral hemorrhage and ischemic stroke. The company is also investigating additional compounds for chronic thrombo-inflammatory and inflammatory conditions.